Vertex spends billions on CRISPR technology in search of diabetes cure

A new billion-dollar agreement with US gene editing firm Arbor Biotechnologies marks a continuation of biotech company Vertex's efforts to develop stem cell treatments, with a special focus on diabetes.

Photo: Brian Snyder/Reuters/Ritzau Scanpix

US-based biotech company Vertex, known for its specialization within cystic fibrosis, has also been working towards a breakthrough for treating type 1 diabetes over the past few years. That innovation is now a step closer.

Vertex has now entered into an agreement with Arbor Biotechnologies, giving it access to Arbor's CRISPR gene editing platform. Vertex is paying an undisclosed sum involving milestone payments of up to DKK 7.6bn (USD 1.2bn), plus a percentage of eventual sales for the priviledge.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Further reading

Related articles

Trial banner

Latest news

See all jobs